Reported Earlier, Telix Pharmaceuticals Posts $230M In Q1 2026 Revenue, Up 11% Quarter-Over-Quarter, Reaffirms FY 2026 Guidance Of $950M-$970M

Benzinga Newsdesk www.benzinga.com Positive 95.5%